TISCH CANCER INSTITUTE AT THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Principal Investigator/Director: Ramon Parsons, MD, PhD ABSTRACT: The mission of the Tisch Cancer Institute is to advance basic, clinical and population health cancer research, so as to prevent cancer in healthy individuals and improve the lives of cancer patients and their families in our diverse communities. To accomplish this mission, the TCI has developed collaborative research programs that strive to translate discoveries to new therapies and to develop new prevention and delivery strategies with priority given to cancers affecting our catchment area. TCI?s four cancer research programs are: Cancer Immunology, Cancer Mechanisms, Cancer Prevention and Control, and Cancer Clinical Investigation. Within its four programs, the TCI has a strong foundation of cancer research with direct cancer-related funding of $53,106,982. This includes peer-reviewed funding of $36,910,750, of which $27,662,959 is NIH funding, including $15,939,357 from the NCI. The TCI fosters intra and inter-programmatic cancer research through strategic planning, pilot project awards, interdisciplinary meetings and retreats, and disease-specific focus groups. In addition, the TCI enables cutting-edge research by providing outstanding cores, equipment, facilities and information technology. TCI supports the following five shared resources: Flow Cytometry, Mouse Genetics, Microscopy, Biostatistics, and Human Immune Monitoring Center, as well as the following three cores-in- development: Biorepository and Pathology Core, Bioinformatics for Next Generation Sequencing, and Biomedical Data Science and Informatics. The Cancer Clinical Trials Office with its newly established Early Phase Trials Unit provides the infrastructure to conduct novel, investigator initiated protocols developed by TCI investigators. The TCI?s catchment area includes the New York City (NYC) neighborhoods of East Harlem, Central Harlem and the Upper East Side, with the Harlems experiencing excess cancer incidence, morbidity and mortality as compared to NYC and the US. In addition, the TCI is the coordinating center for the World Trade Center First Responders Program, and the rescue workers affected by the 9/11 attacks form a distinct and unique component of the TCI catchment area. TCI develops and fosters a dynamic team of scientists, clinical investigators and administrators and provides the research infrastructure support needed to spur new cancer discoveries and improve the outcomes of cancer patients and their families.

Public Health Relevance

TISCH CANCER INSTITUTE AT THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Principal Investigator/Director: Ramon Parsons, MD, PhD Public Health Relevance Statement: The Tisch Cancer Institute provides an infrastructure to advance basic, clinical and population health cancer research, so as to prevent cancer in healthy individuals and improve the lives of cancer patients and their families in our diverse communities. To accomplish this mission, the TCI has developed collaborative research programs that strive to translate discoveries to new therapies and to develop new prevention and delivery strategies with priority given to cancers affecting our catchment area. The Cancer Clinical Trials Office with its newly established Early Phase Trials Unit provides the infrastructure to conduct novel, investigator initiated protocols developed by TCI investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA196521-06
Application #
10022654
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2015-08-01
Project End
2025-07-31
Budget Start
2020-08-11
Budget End
2021-07-31
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Fujiwara, Naoto; Nakagawa, Hayato; Enooku, Kenichiro et al. (2018) CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut 67:1493-1504
Hogstad, Brandon; Berres, Marie-Luise; Chakraborty, Rikhia et al. (2018) RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 215:319-336
Wu, Lisa M; Amidi, Ali; Tanenbaum, Molly L et al. (2018) Computerized cognitive training in prostate cancer patients on androgen deprivation therapy: a pilot study. Support Care Cancer 26:1917-1926
Chang, Sanders; Ru, Meng; Moshier, Erin L et al. (2018) The impact of radiation treatment planning technique on unplanned hospital admissions. Adv Radiat Oncol 3:647-654
Formenti, Silvia C; Rudqvist, Nils-Petter; Golden, Encouse et al. (2018) Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 24:1845-1851
Likhterov, Ilya; Ru, Meng; Ganz, Cindy et al. (2018) Objective and subjective hyposalivation after treatment for head and neck cancer: Long-term outcomes. Laryngoscope 128:2732-2739
Sun, Zhen; Filipescu, Dan; Andrade, Joshua et al. (2018) Transcription-associated histone pruning demarcates macroH2A chromatin domains. Nat Struct Mol Biol 25:958-970
Strub, Thomas; Ghiraldini, Flavia G; Carcamo, Saul et al. (2018) SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling. Nat Commun 9:3440
Buckstein, M; Rhome, R; Ru, M et al. (2018) Neoadjuvant chemoradiation radiation dose levels for surgically resectable esophageal cancer: predictors of use and outcomes. Dis Esophagus 31:
Kamath, Geetanjali R; Taioli, Emanuela; N Egorova, Natalia et al. (2018) Liver Cancer Disparities in New York City: A Neighborhood View of Risk and Harm Reduction Factors. Front Oncol 8:220

Showing the most recent 10 out of 143 publications